Skip to content

CYTOSORBENTS CORPORATION: financial reference

Explore CYTOSORBENTS CORPORATION financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Context from the filing

For CytoSorbents in 2024 and 2025, the filing excludes potentially dilutive securities because their effect is anti-dilutive during losses. The EPS note reconciles reported net loss to the common-share denominator. Dollar losses are displayed in thousands; shares and per-share amounts are unscaled. Full selected share counts and reported USD EPS are preserved. Read the source filing.

For CytoSorbents in 2021 and 2022, outstanding warrants, options and restricted-stock awards are excluded as anti-dilutive. EPS uses net loss attributable to common shareholders, excluding the separate foreign-currency translation component of comprehensive loss. This historical filing displays full dollar losses and full share counts. Its reported USD EPS and share counts are retained. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-12-3144,182,000USD2026-03-30
Total liabilitiesAt date2025-12-3138,279,000USD2026-03-30
Stockholders equityAt date2025-12-315,903,000USD2026-03-30
Cash and cash equivalentsAt date2025-12-316,249,000USD2026-03-30
Net income or loss2025-01-012025-12-31-8,198,000USD2026-03-30
Operating cash flow2025-01-012025-12-31-12,377,000USD2026-03-30
Capital expenditure payments2025-01-012025-12-31164,000USD2026-03-30
Revenue2018-01-012018-12-3122,503,908USD2019-03-07
Financing cash flow2025-01-012025-12-319,309,000USD2026-03-30
Investing cash flow2025-01-012025-12-31-415,000USD2026-03-30
Retained earnings or deficitAt date2025-12-31-312,207,000USD2026-03-30
Basic weighted-average shares2025-01-012025-12-3162,231,771shares2026-03-30
Diluted weighted-average shares2025-01-012025-12-3162,231,771shares2026-03-30
Basic earnings per share2025-01-012025-12-31-0.13USD/shares2026-03-30
Diluted earnings per share2025-01-012025-12-31-0.13USD/shares2026-03-30
Income tax expense or benefit2025-01-012025-12-31-401,000USD2026-03-30
Net property, plant and equipmentAt date2025-12-317,823,000USD2026-03-30
Share-based compensation expense2025-01-012025-12-312,765,000USD2026-03-30
Operating income or loss2025-01-012025-12-31-14,749,000USD2026-03-30
Current assetsAt date2025-12-3120,634,000USD2026-03-30
Current liabilitiesAt date2025-12-319,709,000USD2026-03-30
Current accounts payableAt date2025-12-312,869,000USD2026-03-30
Net finite-lived intangible assetsAt date2025-12-313,226,000USD2026-03-30
Net current accounts receivableAt date2025-12-317,550,000USD2026-03-30
Operating expenses2025-01-012025-12-3141,240,000USD2026-03-30
Net inventoryAt date2025-12-315,281,000USD2026-03-30
Gross profit2025-01-012025-12-3126,491,000USD2026-03-30
Selling, general and administrative expense2025-01-012025-12-3135,645,000USD2026-03-30
Research and development expense2023-01-012023-12-3115,728,915USD2024-03-15

Inspect the source

Entity
CYTOSORBENTS CORPORATION / CIK 0001175151
Captured
2026-09-20T07:44:44.168Z
SEC response SHA-256
8bb195ec858f16302b2a8454a5ffe3eff6c1e6cd0312136a64a7a2f621b86836

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))